Table 4.

Sensitivity analysis

Recommendation	Estimated adjustment based on observations (95% CI)	Adjustment if missing values DO follow recommendations (95% CI)	Adjustment if missing values DO NOT follow recommendations (95% CI)
Diagnosis based on MSU observation	32.0% (28.0–36.3)	32.0% (28.0–36.3)	32.0% (28.0–36.3)
Evaluation of obesity	36.4% (32.2–40.7)	36.4% (32.2–40.7)	36.4% (32.2–40.7)
Evaluation of renal function	65.2% (60.9–69.4)	65.2% (60.9–69.4)	65.2% (60.9–69.4)
Evaluation of lipid profile	77.6% (73.7–81.2)	77.7% (73.8–81.2)	77.4% (73.6–81.0)
Evaluation of arterial pressure	69.0% (64.7–73.0)	69.0% (64.7–73.0)	69.0% (64.7–73.0)
Evaluation of hyperglycemia	57.9% (53.5–62.2)	57.9% (53.5–62.2)	57.9% (53.5–62.2)
Evaluation of alcohol intake	57.1% (52.7–61.5)	57.1% (52.7–61.5)	57.1% (52.7–61.5)
Evaluation of renal lithiasis	23.0% (19.4–26.9)	23.3% (19.7–27.2)	22.9% (19.3–27.3)
Use of hyperuricemic drugs	41.1% (36.8–45.5)	41.1% (36.8–45.5)	41.1% (36.8–45.5)
Evaluation of renal excretion of sUA	35.5% (31.3–39.9)	36.2% (32.0–40.5)	35.2% (31.0–39.5)
Global evaluation of comorbidity	87.5% (84.3–90.3)	87.6% (84.3–90.3)	87.4% (84.1–90.1)
A measure of serum sUA at last visit	95.8% (93.7–97.4)	95.8% (93.7–97.4)	95.8% (93.7–97.4)
Evaluation of flares at the last year	90.7% (87.8–93.1)	90.7% (87.8–93.1)	90.7% (87.8–93.1)
Global evaluation of follow-up	97.4% (95.6–98.6)	97.4% (95.6–98.6)	97.4% (95.6–98.6)
Overweight control	31.2% (27.2–35.5)	31.2% (27.2–35.5)	31.2% (27.2–35.5)
Alcohol intake restriction	56.4% (52.0–60.8)	56.5% (52.1–60.9)	56.3% (51.9–60.7)
Global recommendation on lifestyle	31.2% (27.2–98.6)	31.2% (27.2–98.6)	31.2% (27.2–98.6)
Management of acute flares	100%	100%	100%
Overall management of hyperuricemia	41.1% (36.8–45.5)	41.1% (36.8–45.5)	41.1% (36.8–45.5)
Treatment with allopurinol	90.1% (87.2–92.6)	90.1% (87.2–92.6)	90.1% (87.2–92.6)

MSU monosodium urate, sUA uric acid